drug · small molecule
talazoparib tosylate
Marketedupdated 5mo agoby $PFE PFIZER INC🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.
targets
Poly [ADP-ribose] polymerase 1Poly [ADP-ribose] polymerase 2
all catalysts(0)
nothing on the calendar yet
Trials studying talazoparib tosylate
- phase1Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
- —Korea Post Marketing Surveillance (PMS) Study of Talzenna®
- phase2Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
- phase1Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
- phase1A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 27, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (70)
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 10189837
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Oct 20, 2031compositionUS 8735392
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029method-of-use (U-3651)US 107800882.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 80129762.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029compositionUS 84206502.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
- Jul 27, 2029method-of-use (U-2437)US 98209852.8y
FDA exclusivities (6)
- Jun 20, 2026I-920Indication (3y)
- Jun 20, 2026I-920Indication (3y)
- Jun 20, 2026I-920Indication (3y)
- Jun 20, 2026I-920Indication (3y)
- Jun 20, 2026I-920Indication (3y)
- Jun 20, 2026I-920Indication (3y)
News(1)
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that